CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Toric IOL (SN60T3)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00732030
NCT00732030Phase 4Completed
CompareCT.gov

Evaluation of the Acrysof Toric Model SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.03 Diopters (D)

Alcon Research·interventional·Posted Aug 11, 2008·Updated Apr 7, 2010

In Brief

A Phase 4 clinical trial evaluating Toric IOL (SN60T3) for Cataracts. Completed, enrolled 26 participants across 1 site.

Detailed Summary

Study evaluates the visual outcomes and patient satisfaction after implantation of a toric intraocular lens (IOL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataracts
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 11, 2008
Enrollment StartJun 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.9 years ago

Interventions

Toric IOL (SN60T3)device

Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.